Table 3 Results from IPA analysis of diseases and functions related to thyroid after ¹³¹I and ²¹¹At exposure

²¹¹At

1

0.023

1.4

6

0.32

Dystransthyretinemic euthyroidal hyperthyroxinemia

7.92E−03

UP: TTR

Quantity of L-triiodothyronine

2.65E−03

DOWN: LEP UP: TTR, UCP1

1.4

Differentiated thyroid cancer

4.63E−04

DOWN: IDH1, MMP2, PDGFRA, RAP1GAP, TEK, TGFBR2 UP: CDKN1A, RET,

Medullary thyroid cancer

1.01E−03

DOWN: AMY1A (includes others), PDGFRA, TEK UP: RET,

Thyroid cancer

1.91E−04

DOWN: AMY1A (includes others), ECM1, IDH1, MMP2, PDGFRA, RAP1GAP, SERPINF1, TEK, TGFBR2 UP: CDKN1A, RET

24

0.05

0.5

1.4

11

Metastasis of thyroid gland tumour

1.21E−03

DOWN: VIM UP: RET

Thyroid cancer

1.18E−03

DOWN: AMY1A (includes others), NTRK2, PPARG, SLPI, VIM UP: CDH1, PPARGC1A, PRLR, RAP1GAP, RET, SLC5A8, TP63,

32

Medullary thyroid cancer

1.50E−03

DOWN: AMY1A (includes others), NTRK2 UP: PRLR, RET

Thyroid gland development

4.71E−03

DOWN: HOXA5, TBX1 UP: RET

168

1.8

¹³¹I

24

0.85

Thyroid cancer

1.58E−04

DOWN: AMY1A (includes others), CDKN1A, ECM1, FLT1, MMP2, PPARGC1A, SERPINF1 UP: PPARG, SPP1, TUBA8

8.5

Thyroid cancer

2.05E−03

DOWN: AMY1A (includes others), CDKN1A, MMP2, PPARGC1A, PRLR, SERPINF1 UP: CCND1, PPARG, TUBA8

17

Lack of thyroid gland

9.65E−03

DOWN: FGF10